Compare ARK Genomic Revolution ETF (ARKG) vs Dollar General Corp. (DG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Dollar General Corp. — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Dollar General Corp. trades at $118.92 (market cap $26.23B). The key difference: Dollar General Corp. pays a 1.98% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Dollar General Corp. nearer its low. Which is the better fit depends on your goals.
| ARKG | DG | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $156.26 |
52-Week Low | $23.09 | $95.94 |
Market Cap | — | $26.23B |
Enterprise Value | — | $40.68B |
Dividend Yield | — | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Dollar General (DG) trades at $118.92, up 2.76% today, with a neutral technical signal and bearish moving averages. The stock shows strong valuation metrics with a P/E of 16.82 and P/S of 0.61, supported by three consecutive quarterly earnings beats. Revenue grew to $40.61B in 2025, though net margins compressed to 2.77%. Positive news highlights margin expansion and back-to-school initiatives, while cash flow improved to $395M net.
Outlook remains cautiously optimistic with a $128.45 consensus price target implying 8% upside. Risks include margin pressure from inflation and competitive threats. Analyst consensus is 52% Buy, but weak consumer sentiment and technical resistance near $120 may limit near-term gains. Debt reduction trends and dividend coverage provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
